<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Arcutis Biotherapeutics Inc — News on 6ix</title>
<link>https://6ix.com/company/arcutis-biotherapeutics-inc</link>
<description>Latest news and press releases for Arcutis Biotherapeutics Inc on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Mon, 27 Apr 2026 12:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/arcutis-biotherapeutics-inc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835480b78dffbe2df0e3a70.webp</url>
<title>Arcutis Biotherapeutics Inc</title>
<link>https://6ix.com/company/arcutis-biotherapeutics-inc</link>
</image>
<item>
<title>Arcutis Submits Supplemental New Drug Application to the FDA for ZORYVE® (roflumilast) Cream 0.05% to Expand Indication for Treatment of Atopic Dermatitis to Infants Down to 3 Months</title>
<link>https://6ix.com/company/arcutis-biotherapeutics-inc/news/arcutis-submits-supplemental-new-drug-application-to-the-fda-for-zoryver-roflumilast-cream-005percent-to-expand-indication-for-treatment-of-atopic-dermatitis-to-infants-down-to-3-months</link>
<guid isPermaLink="true">https://6ix.com/company/arcutis-biotherapeutics-inc/news/arcutis-submits-supplemental-new-drug-application-to-the-fda-for-zoryver-roflumilast-cream-005percent-to-expand-indication-for-treatment-of-atopic-dermatitis-to-infants-down-to-3-months</guid>
<pubDate>Mon, 27 Apr 2026 12:00:00 GMT</pubDate>
<description>Submission supported by data from INTEGUMENT-INFANT Phase 2 open-label study in infants aged 3 months to less than 24 months with mild to moderate atopic dermatitisOnce-daily ZORYVE cream was well tolerated with a safety profile consistent with that in older children and adultsAtopic dermatitis impacts 1 million children under the age of 2 in the United StatesOnly one other FDA-approved topical non-steroidal anti-inflammatory agent available for this vulnerable population WESTLAKE VILLAGE, Calif</description>
</item>
<item>
<title>Arcutis’ ZORYVE® (roflumilast) Cream Receives Strong Recommendation in American Academy of Dermatology First-Ever Pediatric Atopic Dermatitis Guidelines</title>
<link>https://6ix.com/company/arcutis-biotherapeutics-inc/news/arcutis-zoryver-roflumilast-cream-receives-strong-recommendation-in-american-academy-of-dermatology-first-ever-pediatric-atopic-dermatitis-guidelines</link>
<guid isPermaLink="true">https://6ix.com/company/arcutis-biotherapeutics-inc/news/arcutis-zoryver-roflumilast-cream-receives-strong-recommendation-in-american-academy-of-dermatology-first-ever-pediatric-atopic-dermatitis-guidelines</guid>
<pubDate>Wed, 22 Apr 2026 12:00:00 GMT</pubDate>
<description>Strong recommendation with high certainty of clinical evidence underscores proven efficacy, safety, and tolerability of ZORYVE cream as a steroid-free topical phosphodiesterase type 4 (PDE4) inhibitorAtopic dermatitis affects approximately 9.6 million children in the United States WESTLAKE VILLAGE, Calif., April 22, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company dedicated to developing meaningful innovations in immuno-dermatolo</description>
</item>
<item>
<title>Arcutis to Report First Quarter 2026 Financial Results and Host Conference Call on May 6, 2026</title>
<link>https://6ix.com/company/arcutis-biotherapeutics-inc/news/arcutis-to-report-first-quarter-2026-financial-results-and-host-conference-call-on-may-6-2026</link>
<guid isPermaLink="true">https://6ix.com/company/arcutis-biotherapeutics-inc/news/arcutis-to-report-first-quarter-2026-financial-results-and-host-conference-call-on-may-6-2026</guid>
<pubDate>Wed, 15 Apr 2026 20:00:00 GMT</pubDate>
<description>WESTLAKE VILLAGE, Calif., April 15, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced that it will report its first quarter 2026 financial results and provide a business update on Wednesday, May 6, 2026 after the U.S. financial markets close. The Company will host a conference call and webcast the same day at 4:30pm ET. A live webcast of the call a</description>
</item>
<item>
<title>Arcutis Management to Present at the 25th Annual Needham Virtual Healthcare Conference</title>
<link>https://6ix.com/company/arcutis-biotherapeutics-inc/news/arcutis-management-to-present-at-the-25th-annual-needham-virtual-healthcare-conference-3</link>
<guid isPermaLink="true">https://6ix.com/company/arcutis-biotherapeutics-inc/news/arcutis-management-to-present-at-the-25th-annual-needham-virtual-healthcare-conference-3</guid>
<pubDate>Tue, 31 Mar 2026 04:00:00 GMT</pubDate>
<description>WESTLAKE VILLAGE, Calif., March 31, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company</description>
</item>
<item>
<title>Arcutis Presents New Phase 2 Results in Infants with Atopic Dermatitis in Late-Breaking Session Today at the 2026 American Academy of Dermatology Annual Meeting</title>
<link>https://6ix.com/company/arcutis-biotherapeutics-inc/news/arcutis-presents-new-phase-2-results-in-infants-with-atopic-dermatitis-in-late-breaking-session-today-at-the-2026-american-academy-of-dermatology-annual-meeting</link>
<guid isPermaLink="true">https://6ix.com/company/arcutis-biotherapeutics-inc/news/arcutis-presents-new-phase-2-results-in-infants-with-atopic-dermatitis-in-late-breaking-session-today-at-the-2026-american-academy-of-dermatology-annual-meeting</guid>
<pubDate>Sat, 28 Mar 2026 04:00:00 GMT</pubDate>
<description>Investigational ZORYVE® (roflumilast) cream 0.05% was well tolerated with safety findings consistent with prior pediatric experience in the INTEGUMENT</description>
</item>
<item>
<title>Arcutis to Present New Clinical Data in a Late-Breaking Podium Presentation and Scientific Posters at the 2026 American Academy of Dermatology Annual Meeting</title>
<link>https://6ix.com/company/arcutis-biotherapeutics-inc/news/arcutis-to-present-new-clinical-data-in-a-late-breaking-podium-presentation-and-scientific-posters-at-the-2026-american-academy-of-dermatology-annual-meeting</link>
<guid isPermaLink="true">https://6ix.com/company/arcutis-biotherapeutics-inc/news/arcutis-to-present-new-clinical-data-in-a-late-breaking-podium-presentation-and-scientific-posters-at-the-2026-american-academy-of-dermatology-annual-meeting</guid>
<pubDate>Wed, 18 Mar 2026 04:00:00 GMT</pubDate>
<description>WESTLAKE VILLAGE, Calif., and DENVER, March 18, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical</description>
</item>
<item>
<title>Arcutis Announces Publication of Positive Long-Term Safety and Efficacy Data with ZORYVE® (roflumilast) Cream 0.05% for Treatment of Mild-to-Moderate Atopic Dermatitis in Children Ages 2–5 in Pediatric Dermatology</title>
<link>https://6ix.com/company/arcutis-biotherapeutics-inc/news/arcutis-announces-publication-of-positive-long-term-safety-and-efficacy-data-with-zoryver-roflumilast-cream-005percent-for-treatment-of-mild-to-moderate-atopic-dermatitis-in-children-ages-2-5-in-pediatric-dermatology</link>
<guid isPermaLink="true">https://6ix.com/company/arcutis-biotherapeutics-inc/news/arcutis-announces-publication-of-positive-long-term-safety-and-efficacy-data-with-zoryver-roflumilast-cream-005percent-for-treatment-of-mild-to-moderate-atopic-dermatitis-in-children-ages-2-5-in-pediatric-dermatology</guid>
<pubDate>Tue, 10 Mar 2026 04:00:00 GMT</pubDate>
<description>ZORYVE foam 0.3% was safe, well-tolerated, and demonstrated durable and continuously improving efficacy in the treatment of seborrheic dermatitis up to 52</description>
</item>
<item>
<title>Arcutis Announces Promotion of Mas Matsuda to Executive Vice President and Chief Legal Officer to Support Next Phase of Growth</title>
<link>https://6ix.com/company/arcutis-biotherapeutics-inc/news/arcutis-announces-promotion-of-mas-matsuda-to-executive-vice-president-and-chief-legal-officer-to-support-next-phase-of-growth-65</link>
<guid isPermaLink="true">https://6ix.com/company/arcutis-biotherapeutics-inc/news/arcutis-announces-promotion-of-mas-matsuda-to-executive-vice-president-and-chief-legal-officer-to-support-next-phase-of-growth-65</guid>
<pubDate>Thu, 05 Mar 2026 05:00:00 GMT</pubDate>
<description>WESTLAKE VILLAGE, Calif., March 05, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company</description>
</item>
<item>
<title>Arcutis Begins Enrolling Phase 1a/1b Study Evaluating ARQ-234, a CD200R Agonist, in Healthy Volunteers and Adults With Atopic Dermatitis</title>
<link>https://6ix.com/company/arcutis-biotherapeutics-inc/news/arcutis-begins-enrolling-phase-1a1b-study-evaluating-arq-234-a-cd200r-agonist-in-healthy-volunteers-and-adults-with-atopic-dermatitis</link>
<guid isPermaLink="true">https://6ix.com/company/arcutis-biotherapeutics-inc/news/arcutis-begins-enrolling-phase-1a1b-study-evaluating-arq-234-a-cd200r-agonist-in-healthy-volunteers-and-adults-with-atopic-dermatitis</guid>
<pubDate>Tue, 03 Mar 2026 05:00:00 GMT</pubDate>
<description>Phase 1a/1b, first-in-human study to evaluate safety and tolerability for investigational ARQ-234 in healthy volunteers and adults with moderate to severe</description>
</item>
<item>
<title>Arcutis Management to Present at TD Cowen’s 46th Annual Health Care Conference</title>
<link>https://6ix.com/company/arcutis-biotherapeutics-inc/news/arcutis-management-to-present-at-td-cowens-46th-annual-health-care-conference</link>
<guid isPermaLink="true">https://6ix.com/company/arcutis-biotherapeutics-inc/news/arcutis-management-to-present-at-td-cowens-46th-annual-health-care-conference</guid>
<pubDate>Fri, 27 Feb 2026 05:00:00 GMT</pubDate>
<description>WESTLAKE VILLAGE, Calif., Feb. 27, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused</description>
</item>
<item>
<title>Arcutis Announces Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update</title>
<link>https://6ix.com/company/arcutis-biotherapeutics-inc/news/arcutis-announces-fourth-quarter-and-full-year-2025-financial-results-and-provides-business-update</link>
<guid isPermaLink="true">https://6ix.com/company/arcutis-biotherapeutics-inc/news/arcutis-announces-fourth-quarter-and-full-year-2025-financial-results-and-provides-business-update</guid>
<pubDate>Wed, 25 Feb 2026 05:00:00 GMT</pubDate>
<description>Q4 2025 net product revenue for ZORYVE® (roflumilast) was $127.5 million, an 84% increase compared to Q4 2024, and a 29% increase compared to Q3 2025Full year</description>
</item>
<item>
<title>Professional Golfer Max Homa Joins Arcutis’ Free to Be Me Campaign, Urging Individuals with Seborrheic Dermatitis to Tee Up a Conversation with Their Healthcare Provider About Long-Term Treatments</title>
<link>https://6ix.com/company/arcutis-biotherapeutics-inc/news/professional-golfer-max-homa-joins-arcutis-free-to-be-me-campaign-urging-individuals-with-seborrheic-dermatitis-to-tee-up-a-conversation-with-their-healthcare-provider-about-long-term-treatments</link>
<guid isPermaLink="true">https://6ix.com/company/arcutis-biotherapeutics-inc/news/professional-golfer-max-homa-joins-arcutis-free-to-be-me-campaign-urging-individuals-with-seborrheic-dermatitis-to-tee-up-a-conversation-with-their-healthcare-provider-about-long-term-treatments</guid>
<pubDate>Tue, 24 Feb 2026 14:15:00 GMT</pubDate>
<description>Max Homa shares his journey with seborrheic dermatitis to encourage others to take control of their symptomsZORYVE® (roflumilast) foam 0.3% is a once-daily, steroid-free, leave-in topical foam uniquely formulated to treat the itching, redness, and flaking of seborrheic dermatitis anywhere it appears, including hair-bearing areas10 million Americans live with seborrheic dermatitis, a chronic inflammatory skin disease that occurs most often on areas with oil-producing glands, including the face an</description>
</item>
<item>
<title>Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)</title>
<link>https://6ix.com/company/arcutis-biotherapeutics-inc/news/arcutis-biotherapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635c4</link>
<guid isPermaLink="true">https://6ix.com/company/arcutis-biotherapeutics-inc/news/arcutis-biotherapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635c4</guid>
<pubDate>Thu, 05 Feb 2026 05:00:00 GMT</pubDate>
<description>WESTLAKE VILLAGE, Calif., March 14, 2022 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on</description>
</item>
<item>
<title>Arcutis Announces Positive Topline Results for INTEGUMENT-INFANT Phase 2 Trial of ZORYVE® (roflumilast) Cream 0.05% in Infants with Mild to Moderate Atopic Dermatitis</title>
<link>https://6ix.com/company/arcutis-biotherapeutics-inc/news/arcutis-announces-positive-topline-results-integument-infant-phase-2-trial-zoryver</link>
<guid isPermaLink="true">https://6ix.com/company/arcutis-biotherapeutics-inc/news/arcutis-announces-positive-topline-results-integument-infant-phase-2-trial-zoryver</guid>
<pubDate>Mon, 02 Feb 2026 05:00:00 GMT</pubDate>
<description>58% of participants achieved a 75% improvement in Eczema Area and Severity Index (EASI-75) with ZORYVE cream 0.05% at Week 4Investigational ZORYVE cream 0.05%</description>
</item>
<item>
<title>Arcutis Biotherapeutics, Inc. Announces Termination of Promotion Agreement with Kowa</title>
<link>https://6ix.com/company/arcutis-biotherapeutics-inc/news/arcutis-biotherapeutics-inc-announces-termination-promotion-agreement-kowa-2026-01-26</link>
<guid isPermaLink="true">https://6ix.com/company/arcutis-biotherapeutics-inc/news/arcutis-biotherapeutics-inc-announces-termination-promotion-agreement-kowa-2026-01-26</guid>
<pubDate>Mon, 26 Jan 2026 05:00:00 GMT</pubDate>
<description>WESTLAKE VILLAGE, Calif., Jan. 26, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused</description>
</item>
<item>
<title>Arcutis to Report Fourth Quarter and Full Year 2025 Financial Results and Present at Upcoming Investor Conference</title>
<link>https://6ix.com/company/arcutis-biotherapeutics-inc/news/arcutis-report-fourth-quarter-and-full-year-2025-financial-results-and-present</link>
<guid isPermaLink="true">https://6ix.com/company/arcutis-biotherapeutics-inc/news/arcutis-report-fourth-quarter-and-full-year-2025-financial-results-and-present</guid>
<pubDate>Thu, 22 Jan 2026 05:00:00 GMT</pubDate>
<description>Fourth quarter and full year 2025 investor conference call scheduled for February 25, 2026 at 4:30 p.m. ETArcutis management to present at the Guggenheim</description>
</item>
<item>
<title>Nationwide Survey Underscores Concerns with Use of Topical Steroids and Need for Long-Term Treatment Strategies Facing the 46 Million Americans with Chronic Inflammatory Skin Conditions</title>
<link>https://6ix.com/company/arcutis-biotherapeutics-inc/news/nationwide-survey-underscores-concerns-topical-130000361</link>
<guid isPermaLink="true">https://6ix.com/company/arcutis-biotherapeutics-inc/news/nationwide-survey-underscores-concerns-topical-130000361</guid>
<pubDate>Wed, 21 Jan 2026 13:00:00 GMT</pubDate>
<description>Nearly 9 in 10 adults and parents of children with plaque psoriasis, atopic dermatitis, and seborrheic dermatitis being treated with topical steroids are concerned about side effectsNearly 8 in 10 adults and parents agreed that their or their child's treatment plan focuses on reactively “taming a flare” rather than proactive long-term solutionsWhen their skin condition is uncontrolled, nearly all adults and children experience emotional, mental, and daily life challenges WESTLAKE VILLAGE, Calif.</description>
</item>
<item>
<title>Arcutis Highlights 2026 Strategic Priorities and Anticipated Milestones</title>
<link>https://6ix.com/company/arcutis-biotherapeutics-inc/news/arcutis-highlights-2026-strategic-priorities-and-anticipated-milestones-2026-01-12</link>
<guid isPermaLink="true">https://6ix.com/company/arcutis-biotherapeutics-inc/news/arcutis-highlights-2026-strategic-priorities-and-anticipated-milestones-2026-01-12</guid>
<pubDate>Mon, 12 Jan 2026 05:00:00 GMT</pubDate>
<description>Continued strong growth of ZORYVE® (roflumilast) in 2026 with full-year net product sales guidance of $455–$470 millionAdvancement of ZORYVE</description>
</item>
<item>
<title>Arcutis Strengthens Board of Directors with New Appointment of Amit Munshi and Honors Retirement of Bhaskar Chaudhuri</title>
<link>https://6ix.com/company/arcutis-biotherapeutics-inc/news/arcutis-strengthens-board-directors-new-appointment-amit-munshi-and-honors-retirement</link>
<guid isPermaLink="true">https://6ix.com/company/arcutis-biotherapeutics-inc/news/arcutis-strengthens-board-directors-new-appointment-amit-munshi-and-honors-retirement</guid>
<pubDate>Mon, 08 Dec 2025 05:00:00 GMT</pubDate>
<description>WESTLAKE VILLAGE, Calif., Dec. 08, 2025 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused</description>
</item>
<item>
<title>FDA Accepts Supplemental New Drug Application for Arcutis’ ZORYVE® (roflumilast) Cream 0.3% for the Treatment of Plaque Psoriasis in Children Ages 2 to 5</title>
<link>https://6ix.com/company/arcutis-biotherapeutics-inc/news/fda-accepts-supplemental-new-drug-application-arcutis-zoryver-roflumilast-cream-03</link>
<guid isPermaLink="true">https://6ix.com/company/arcutis-biotherapeutics-inc/news/fda-accepts-supplemental-new-drug-application-arcutis-zoryver-roflumilast-cream-03</guid>
<pubDate>Mon, 17 Nov 2025 05:00:00 GMT</pubDate>
<description>Prescription Drug User Fee Act (PDUFA) target action date set for June 29, 2026If approved, ZORYVE cream 0.3% would be the first and only topical PDE4</description>
</item>
</channel>
</rss>